Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Improving diabetes-related family functioning and mutual family involvement with co-created family dialogue tools

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  2. Characteristics associated with non-disclosure of Type 2 diabetes at work

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
To assess the effect of liraglutide, a once-daily human glucagon-like peptide-1 analogue on pancreatic B-cell function. methods: Patients with Type 2 diabetes (n = 39) were randomized to treatment with 0.65, 1.25 or 1.9 mg/day liraglutide or placebo for 14 weeks. First- and second-phase insulin release were measured by means of the insulin-modified frequently sampled intravenous glucose tolerance test. Arginine-stimulated insulin secretion was measured during a hyperglycaemic clamp (20 mmol/l). Glucose effectiveness and insulin sensitivity were estimated by means of the insulin-modified frequently sampled intravenous glucose tolerance test.
Original languageEnglish
JournalDiabetic Medicine
Volume25
Issue number2
Pages (from-to)152-6
Number of pages5
ISSN0742-3071
DOIs
Publication statusPublished - 1 Feb 2008

ID: 32267625